Journal of Emergencies, Trauma, and Shock
Home About us Editors Ahead of Print Current Issue Archives Search Instructions Subscribe Advertise Login 
Users online:429   Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size   
BASIC SCIENCE STUDY
Year : 2010  |  Volume : 3  |  Issue : 1  |  Page : 26-35

A biomarker panel to discriminate between systemic inflammatory response syndrome and sepsis and sepsis severity


1 Department of Molecular Diagnostics, Philips Research, High Tech Campus 12a, 5656 AE Eindhoven, Netherlands
2 Experimental Anesthesiology, University Hospital Ulm, Steinhoevelstr. 9, 89075 Ulm, Germany
3 Philips Research North America, 345 Scarborough Road, Briarcliff Manor, NY 10510, USA
4 Natural and Medical Sciences Institute, University of Tuebingen, Markwiesenstr. 55, 72770 Reutlingen, Germany
5 Clinical Anesthesiology, University Hospital Ulm, Steinhoevelstr. 9, 89075 Ulm, Germany

Correspondence Address:
Chamindie Punyadeera
Department of Molecular Diagnostics, Philips Research, High Tech Campus 12a, 5656 AE Eindhoven
Netherlands
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0974-2700.58666

Rights and Permissions

Introduction: In this study, we report on initial efforts to discover putative biomarkers for differential diagnosis of a systemic inflammatory response syndrome (SIRS) versus sepsis; and different stages of sepsis. In addition, we also investigated whether there are proteins that can discriminate between patients who survived sepsis from those who did not. Materials and Methods: Our study group consisted of 16 patients, of which 6 died and 10 survived. We daily measured 28 plasma proteins, for the whole stay of the patients in the ICU. Results: We observed that metalloproteinases and sE-selectin play a role in the distinction between SIRS and sepsis, and that IL-1α, IP-10, sTNF-R2 and sFas appear to be indicative for the progression from sepsis to septic shock. A combined measurement of MMP-3, -10, IL-1α, IP-10, sIL-2R, sFas, sTNF-R1, sRAGE, GM-CSF, IL-1β and Eotaxin allows for a good separation of patients that survived from those that died (mortality prediction with a sensitivity of 79% and specificity of 86%). Correlation analysis suggests a novel interaction between IL-1a and IP-10. Conclusion: The marker panel is ready to be verified in a validation study with or without therapeutic intervention


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed6414    
    Printed370    
    Emailed1    
    PDF Downloaded215    
    Comments [Add]    
    Cited by others 31    

Recommend this journal